High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration

Annals of Pharmacotherapy

Volumn 44, Issue 10, 2010, Pages 1660-1664

  Utrup, Theresa R ^a   Mueller, Eric W ^b,c   Healy, Daniel P ^c   Callcut, Rachael A ^d   Peterson, John D ^e,f   Hurford, William E ^g  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d STANFORD UNIVERSITY   (United States)

^e UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^f Anesthesia Consulting Services   (United States)

^g UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

Author keywords

Ciprofloxacin; Continuous venovenous hemodiafiltration; Critically ill; Obese; Osteomyelitis; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CEFEPIME; CIPROFLOXACIN; COLISTIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B;

ABDOMINAL BLEEDING; ACINETOBACTER INFECTION; ACUTE KIDNEY FAILURE; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIUM ISOLATION; BILIRUBIN BLOOD LEVEL; BODY MASS; BONE GRAFT; CASE REPORT; COMMINUTED FRACTURE; CONTINUOUS HEMODIAFILTRATION; CRITICALLY ILL PATIENT; DEBRIDEMENT; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; ENTEROBACTER AEROGENES; ENTEROBACTERIACEAE INFECTION; HEMATOMA; HEMORRHAGIC SHOCK; HOSPITALIZATION; HUMAN; HUMAN TISSUE; INTENSIVE CARE UNIT; INTERNATIONAL NORMALIZED RATIO; LAPAROTOMY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE ORGAN FAILURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OSTEOMYELITIS; PERITONEUM LAVAGE; PRIORITY JOURNAL; RESPIRATORY FAILURE; SENSORY DYSFUNCTION; SEPTIC SHOCK; SOFT TISSUE INFECTION; SPINE FUSION; SPLENECTOMY; STEADY STATE; SUBPHRENIC ABSCESS; THERAPY EFFECT; TISSUE CULTURE; TREATMENT DURATION; TREATMENT RESPONSE; VACUUM ASSISTED CLOSURE; VERTEBRAL CANAL STENOSIS; WOUND DEHISCENCE; WOUND IRRIGATION;

ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; CRITICAL ILLNESS; ENTEROBACTER AEROGENES; ENTEROBACTERIACEAE INFECTIONS; FATAL OUTCOME; HEMODIAFILTRATION; HUMANS; INFUSIONS, INTRAVENOUS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; OBESITY; OSTEOMYELITIS; SPINAL FRACTURES;

EID: 77957659759     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P234     Document Type: Article

References (14)

1. National Heart and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. NIH Publication 98-4083. www.nhlbi.nih.gov/guidelines/obesity/ob-gdlns.pdf (accessed 2009 May 29).
2. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005;41:1159-66. DOI 10.1086/444500
3. Liang H, Kays MB, Sowinski KM. Separation of levofloxacin, ciprofloxacin, gatifloxacin, moxifloxacin, trovafloxacin, and cinoxacin by high-performance liquid chromatography: application to levofloxacin determination in human plasma. J Chromatogr B 2002;772:53-63. DOI 10.1016/S1570-0232(02)00046-6
4. Reetze-Bonorden P, Bohler J, Keller E. Drug dosing in patients during continuous renal replacement therapy pharmacokinetic and therapeutic considerations. Clin Pharmacokinet 1993;24:362-79. DOI 10.2165/00003088- 199324050-00002
5. Schetz M, Ferdinande P, Van den Berghe G, Verwaest C, Lauwers P. Pharmacokinetics of continuous renal replacement therapy. Intensive Care Med 1995;21:612-20. DOI 10.1007/BF01700172
6. Pfeffer M. Estimation of mean residence time from data obtained when multiple-dosing steady state has been reached. J Pharm Sci 1984;73:854-6. DOI 10.1002/jps.2600730645
7. Benet LZ, Galeazzi RL. Noncompartmental determination of steady-state volume of distribution. J Pharm Sci 1979;68:1071-4. DOI 10.1002/jps.2600680845
8. Malone RS, Fish DN, Abraham E, Teitelbaum I. Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2001;45:2949-54. DOI 10.1128/AAC.45.10.2949-2954.2001
9. Wallis SC, Mullany DV, Lipman J, Rickard CM, Daley PJ. Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration. Intensive Care Med 2001;27:665-72. DOI 10.1007/s001340100857
10. Product information. Cipro (ciprofloxacin). Bayer Heathcare Pharmaceuticals Inc., October 2008. www.univgraph.com/bayer/inserts/ciproiv.pdf (accessed 2009 June 8).
11. Hollenstein UM, Brunner M, Schmid R, Müller M. Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing. Int J Obesity 2001;25:354-8. DOI 10.1038/sj.ijo.0801555
12. Forrest A, Nix DE, Ballow CH, Goss TF, Birminghan MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073-81.
13. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 1999;58:S29-36. DOI 10.2165/00003495-199958002-00006
14. Sader HS, Fritsche TR, Jones RN. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003). Diagnos Microbiol Infect Dis 2005;52:265-73. DOI 10.1016/j.diagmicrobio.2005.02.003